{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T15:02:42Z","timestamp":1784991762267,"version":"3.55.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T00:00:00Z","timestamp":1626393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T00:00:00Z","timestamp":1626393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Late infantile neuronal ceroid lipofuscinosis (CLN2 Batten disease) is a rare, progressive neurodegenerative disease of childhood. The natural history of motor and language regression is used to monitor the efficacy of CNS treatments. Less is known about CLN2 retinopathy. Our aim is to elaborate the nature, age of onset, and symmetry of CLN2 retinopathy using visual electrophysiology and ophthalmic imaging.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Subjects and methods<\/jats:title>\n                <jats:p>We reviewed 22 patients with genetically confirmed CLN2 disease; seventeen showing classical and five atypical disease. Flash electroretinograms (ERGs), flash and pattern reversal visual evoked potentials (VEPs), recorded from awake children were collated. Available fundus images were graded, optical coherence tomography (OCT) central subfoveal thickness (CST) measured, and genotype, age, clinical vision assessment and motor language grades assembled.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>ERGs show cone\/rod system dysfunction preceded by localised macular ellipsoid zone disruption on OCT from 4.8 years. Electroencephalogram (EEG) time-locked spikes confounded both pattern 6\/17 (35%) and flash VEPs 12\/16 (75%). Paired right eye (RE) and left eye (LE) ERG amplitudes did not differ significantly for each flash stimulus at the <jats:italic>p<\/jats:italic> 0.001 level, Wilcoxon ranked signed test. Cone ERGs show a functional deficit before CST thinning in classical disease. Optomap hyper fundus autofluorescence (FAF) at the fovea was noted in three patients with normal ERGs. The oldest patient showed an ovoid aggregate above the external limiting membrane at the fovea, which did not affect the PERG.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>ERG findings in CLN2 retinopathy show symmetrical cone-rod dysfunction, from 4y10m in this series, but a broad range of ages when ERG function is preserved.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41433-021-01594-y","type":"journal-article","created":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T16:21:07Z","timestamp":1626452467000},"page":"2438-2448","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["An ERG and OCT study of neuronal ceroid lipofuscinosis CLN2 Battens retinopathy"],"prefix":"10.1038","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5491-3911","authenticated-orcid":false,"given":"Dorothy A.","family":"Thompson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si\u00e2n E.","family":"Handley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5250-6404","authenticated-orcid":false,"given":"Robert H.","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2022-3669","authenticated-orcid":false,"given":"Oliver R.","family":"Marmoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9712-6122","authenticated-orcid":false,"given":"Paul","family":"Gissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,16]]},"reference":[{"key":"1594_CR1","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1212\/WNL.0b013e31825f0547","volume":"79","author":"RE Williams","year":"2012","unstructured":"Williams RE, Mole SE. New nomenclature and classification scheme for the neuronal ceroid lipofuscinoses. Neurology. 2012;79:183\u201391.","journal-title":"Neurology"},{"key":"1594_CR2","first-page":"386","volume":"23","author":"F Batten","year":"1903","unstructured":"Batten F. Cerebral degeneration with symmetrical changes in the macula in two members of a family. Trans Ophthalmol Soc UK. 1903;23:386\u201390.","journal-title":"Trans Ophthalmol Soc UK"},{"key":"1594_CR3","doi-asserted-by":"crossref","unstructured":"Specchio N, Ferretti A, Trivisano M, Pietrafusa N, Pepi C, Calabrese C, et al. Neuronal ceroid lipofuscinosis: potential for targeted therapy. Drugs. 2020;81:101\u201323.","DOI":"10.1007\/s40265-020-01440-7"},{"key":"1594_CR4","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2147\/TCRM.S241048","volume":"16","author":"N Specchio","year":"2020","unstructured":"Specchio N, Pietrafusa N, Trivisano M. Changing times for CLN2 disease: the era of enzyme replacement therapy. Ther Clin Risk Manag. 2020;16:213\u201322.","journal-title":"Ther Clin Risk Manag"},{"key":"1594_CR5","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1136\/bjo.2006.091637","volume":"90","author":"J Collins","year":"2006","unstructured":"Collins J, Holder GE, Herbert H, Adams GG. Batten disease: features to facilitate early diagnosis. Br J Ophthalmol. 2006;90:1119\u201324.","journal-title":"Br J Ophthalmol"},{"key":"1594_CR6","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ajo.2020.07.015","volume":"220","author":"S Dulz","year":"2020","unstructured":"Dulz S, Atiskova Y, Wibbeler E, Wildner J, Wagenfeld L, Schwering C, et al. An ophthalmic rating scale to assess ocular involvement in juvenile CLN3 disease. Am J Ophthalmol. 2020;220:64\u201371.","journal-title":"Am J Ophthalmol"},{"key":"1594_CR7","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1006\/geno.1998.5328","volume":"50","author":"CG Liu","year":"1998","unstructured":"Liu CG, Sleat DE, Donnelly RJ, Lobel P. Structural organization and sequence of CLN2, the defective gene in classical late infantile neuronal ceroid lipofuscinosis. Genomics. 1998;50:206\u201312.","journal-title":"Genomics"},{"key":"1594_CR8","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00401-008-0349-3","volume":"116","author":"M Elleder","year":"2008","unstructured":"Elleder M, Dvorakova L, Stolnaja L, Vlaskova H, Hulkova H, Druga R, et al. Atypical CLN2 with later onset and prolonged course: a neuropathologic study showing different sensitivity of neuronal subpopulations to TPP1 deficiency. Acta Neuropathol. 2008;116:119\u201324.","journal-title":"Acta Neuropathol"},{"key":"1594_CR9","doi-asserted-by":"publisher","first-page":"100718","DOI":"10.1016\/j.ymgmr.2021.100718","volume":"27","author":"OM Espitia Segura","year":"2021","unstructured":"Espitia Segura OM, Hernandez Z, Mancilla NI, Naranjo RA, Tavera L. Real world effectiveness of cerliponase alfa in classical and atypical patients. a case series. Mol Genet Metab Rep. 2021;27:100718.","journal-title":"Mol Genet Metab Rep"},{"key":"1594_CR10","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.ymgme.2016.07.011","volume":"119","author":"M Fietz","year":"2016","unstructured":"Fietz M, AlSayed M, Burke D, Cohen-Pfeffer J, Cooper JD, Dvorakova L, et al. Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): expert recommendations for early detection and laboratory diagnosis. Mol Genet Metab. 2016;119:160\u20137.","journal-title":"Mol Genet Metab"},{"issue":"3","key":"1594_CR11","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41582-019-0138-8","volume":"15","author":"TB Johnson","year":"2019","unstructured":"Johnson TB, Cain JT, White KA, Ramirez-Montealegre D, Pearce DA, Weimer JM. Therapeutic landscape for Batten disease: current treatments and future prospects. Nat Rev Neurol. 2019;15(3):161\u201378.","journal-title":"Nat Rev Neurol"},{"key":"1594_CR12","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s40265-017-0771-8","volume":"77","author":"A Markham","year":"2017","unstructured":"Markham A. Cerliponase alfa: first global approval. Drugs. 2017;77:1247\u20139.","journal-title":"Drugs"},{"key":"1594_CR13","unstructured":"NICE NIfHaCE. Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2: https:\/\/www.nice.org.uk\/guidance\/hst12\/chapter\/1-Recommendations; 2019."},{"key":"1594_CR14","unstructured":"FDA. Brineura (cerliponase alfa) Injection: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/761052Orig1s000TOC.cfm; 2017."},{"key":"1594_CR15","unstructured":"EMA. Human medicine European public assessment report (EPAR): Brineura: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/brineura; 2017."},{"key":"1594_CR16","doi-asserted-by":"crossref","unstructured":"Sondhi D, Kaminsky SM, Hackett NR, Pagovich OE, Rosenberg JB, De BP, et al. Slowing late infantile Batten disease by direct brain parenchymal administration of a rh.10 adeno-associated virus expressing CLN2. Sci Transl Med. 2020;12:1\u201312.","DOI":"10.1126\/scitranslmed.abb5413"},{"key":"1594_CR17","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1056\/NEJMoa1712649","volume":"378","author":"A Schulz","year":"2018","unstructured":"Schulz A, Ajayi T, Specchio N, de Los Reyes E, Gissen P, Ballon D, et al. Study of intraventricular cerliponase alfa for CLN2 disease. N Engl J Med. 2018;378:1898\u2013907.","journal-title":"N Engl J Med"},{"key":"1594_CR18","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.exer.2014.06.008","volume":"125","author":"RE Whiting","year":"2014","unstructured":"Whiting RE, Narfstrom K, Yao G, Pearce JW, Coates JR, Castaner LJ, et al. Enzyme replacement therapy delays pupillary light reflex deficits in a canine model of late infantile neuronal ceroid lipofuscinosis. Exp Eye Res. 2014;125:164\u201372.","journal-title":"Exp Eye Res"},{"key":"1594_CR19","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/s41583-018-0070-8","volume":"19","author":"JV Forrester","year":"2018","unstructured":"Forrester JV, McMenamin PG, Dando SJ. CNS infection and immune privilege. Nat Rev Neurosci. 2018;19:655\u201371.","journal-title":"Nat Rev Neurosci"},{"key":"1594_CR20","doi-asserted-by":"publisher","first-page":"108130","DOI":"10.1016\/j.exer.2020.108130","volume":"197","author":"REH Whiting","year":"2020","unstructured":"Whiting REH, Pearce JW, Vansteenkiste DP, Bibi K, Lim S, Robinson Kick G, et al. Intravitreal enzyme replacement preserves retinal structure and function in canine CLN2 neuronal ceroid lipofuscinosis. Exp Eye Res. 2020;197:108130.","journal-title":"Exp Eye Res"},{"key":"1594_CR21","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/ajmg.10660","volume":"112","author":"R Steinfeld","year":"2002","unstructured":"Steinfeld R, Heim P, von Gregory H, Meyer K, Ullrich K, Goebel HH, et al. Late infantile neuronal ceroid lipofuscinosis: quantitative description of the clinical course in patients with CLN2 mutations. Am J Med Genet. 2002;112:347\u201354.","journal-title":"Am J Med Genet"},{"key":"1594_CR22","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1212\/01.wnl.0000267885.47092.40","volume":"69","author":"S Worgall","year":"2007","unstructured":"Worgall S, Kekatpure MV, Heier L, Ballon D, Dyke JP, Shungu D, et al. Neurological deterioration in late infantile neuronal ceroid lipofuscinosis. Neurology 2007;69:521\u201335.","journal-title":"Neurology"},{"key":"1594_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2326409818788382","volume":"6","author":"KW Wyrwich","year":"2018","unstructured":"Wyrwich KW, Schulz A, Nickel M, Slasor P, Ajayi T, Jacoby TR, Kohlschutter A. An adapted clinical measurement tool for the key symptoms of CLN2 disease. J Inborn Errors Metab Screen. 2018;6:1\u20137.","journal-title":"J Inborn Errors Metab Screen"},{"key":"1594_CR24","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/S2352-4642(18)30179-2","volume":"2","author":"M Nickel","year":"2018","unstructured":"Nickel M, Simonati A, Jacoby D, Lezius S, Kilian D, Van de Graaf B, et al. Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study. Lancet Child Adolesc Health. 2018;2:582\u201390.","journal-title":"Lancet Child Adolesc Health"},{"key":"1594_CR25","doi-asserted-by":"publisher","first-page":"e73128","DOI":"10.1371\/journal.pone.0073128","volume":"8","author":"A Orlin","year":"2013","unstructured":"Orlin A, Sondhi D, Witmer MT, Wessel MM, Mezey JG, Kaminsky SM, et al. Spectrum of ocular manifestations in CLN2-associated batten (Jansky\u2013Bielschowsky) disease correlate with advancing age and deteriorating neurological function. PLoS ONE. 2013;8:e73128.","journal-title":"PLoS ONE"},{"key":"1594_CR26","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.oret.2020.01.011","volume":"4","author":"KD Kovacs","year":"2020","unstructured":"Kovacs KD, Patel S, Orlin A, Kim K, Van Everen S, Conner T, et al. Symmetric age association of retinal degeneration in patients with CLN2-associated batten disease. Ophthalmol Retin. 2020;4:728\u201336.","journal-title":"Ophthalmol Retin"},{"key":"1594_CR27","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/eye.1998.148","volume":"12","author":"RG Weleber","year":"1998","unstructured":"Weleber RG. The dystrophic retina in multisystem disorders: the electroretinogram in neuronal ceroid lipofuscinoses. Eye. 1998;12:580\u201390.","journal-title":"Eye"},{"key":"1594_CR28","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ymgme.2004.06.019","volume":"83","author":"RG Weleber","year":"2004","unstructured":"Weleber RG, Gupta N, Trzupek KM, Wepner MS, Kurz DE, Milam AH. Electroretinographic and clinicopathologic correlations of retinal dysfunction in infantile neuronal ceroid lipofuscinosis (infantile Batten disease). Mol Genet Metab. 2004;83:128\u201337.","journal-title":"Mol Genet Metab"},{"key":"1594_CR29","doi-asserted-by":"publisher","unstructured":"Marmoy OR, Moinuddin M, Thompson DA. An alternative electroretinographic protocol for children: a study of diagnostic agreement and accuracy relative to ISCEV standard electroretinograms. Acta Ophthalmol. 2021 14 June 2021. https:\/\/doi.org\/10.1111\/aos.14938.","DOI":"10.1111\/aos.14938"},{"key":"1594_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10633-014-9473-7","volume":"130","author":"DL McCulloch","year":"2015","unstructured":"McCulloch DL, Marmor MF, Brigell MG, Hamilton R, Holder GE, Tzekov R, et al. ISCEV Standard for full-field clinical electroretinography (2015 update). Doc Ophthalmol. 2015;130:1\u201312.","journal-title":"Doc Ophthalmol"},{"key":"1594_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10633-016-9553-y","volume":"133","author":"JV Odom","year":"2016","unstructured":"Odom JV, Bach M, Brigell M, Holder GE, McCulloch DL, Mizota A, et al. ISCEV standard for clinical visual evoked potentials: (2016 update). Doc Ophthalmol. 2016;133:1\u20139.","journal-title":"Doc Ophthalmol"},{"key":"1594_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10633-012-9353-y","volume":"126","author":"M Bach","year":"2013","unstructured":"Bach M, Brigell MG, Hawlina M, Holder GE, Johnson MA, McCulloch DL, et al. ISCEV standard for clinical pattern electroretinography (PERG): 2012 update. Doc Ophthalmol. 2013;126:1\u20137.","journal-title":"Doc Ophthalmol"},{"key":"1594_CR33","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1002\/humu.23860","volume":"40","author":"E Gardner","year":"2019","unstructured":"Gardner E, Bailey M, Schulz A, Aristorena M, Miller N, Mole SE. Mutation update: Review of TPP1 gene variants associated with neuronal ceroid lipofuscinosis CLN2 disease. Hum Mutat. 2019;40:1924\u201338.","journal-title":"Hum Mutat"},{"key":"1594_CR34","doi-asserted-by":"publisher","first-page":"215","DOI":"10.5935\/0004-2749.20170053","volume":"80","author":"E Quagliato","year":"2017","unstructured":"Quagliato E, Rocha DM, Sacai PY, Watanabe SS, Salomao SR, Berezovsky A. Retinal function in patients with the neuronal ceroid lipofuscinosis phenotype. Arq Bras Oftalmol. 2017;80:215\u20139.","journal-title":"Arq Bras Oftalmol"},{"key":"1594_CR35","first-page":"27","volume":"122","author":"M Modrzejewska","year":"2020","unstructured":"Modrzejewska M, Kirkiewicz M, Kiszkielis A, Lubi\u0144ski W. Ophthalmologic symptoms and diagnosis of a patient with Jansky\u2013Bielschowsky disease. Klinika Ocz\/Acta Ophthalmol Polon. 2020;122:27\u201330.","journal-title":"Klinika Ocz\/Acta Ophthalmol Polon"},{"key":"1594_CR36","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/dmcn.14346","volume":"62","author":"B Dozieres-Puyravel","year":"2020","unstructured":"Dozieres-Puyravel B, Nasser H, Elmaleh-Berges M, Lopez Hernandez E, Gelot A, Ilea A, et al. Paediatric-onset neuronal ceroid lipofuscinosis: first symptoms and presentation at diagnosis. Dev Med Child Neurol. 2020;62:528\u201330.","journal-title":"Dev Med Child Neurol"},{"key":"1594_CR37","first-page":"1","volume":"1","author":"GA Osterberg","year":"1935","unstructured":"Osterberg GA. Topography of the layer of rods and cones in the human retina. Acta Ophthalmol Suppl. 1935;1:1\u2013103.","journal-title":"Acta Ophthalmol Suppl"},{"key":"1594_CR38","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1126\/science.3576186","volume":"236","author":"CA Curcio","year":"1987","unstructured":"Curcio CA, Sloan KR Jr., Packer O, Hendrickson AE, Kalina RE. Distribution of cones in human and monkey retina: individual variability and radial asymmetry. Science 1987;236:579\u201382.","journal-title":"Science"},{"key":"1594_CR39","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/BF02334164","volume":"225","author":"EI Traboulsi","year":"1987","unstructured":"Traboulsi EI, Green WR, Luckenbach MW, de la Cruz ZC. Neuronal ceroid lipofuscinosis. Ocular histopathologic and electron microscopic studies in the late infantile, juvenile, and adult forms. Graefes Arch Clin Exp Ophthalmol. 1987;225:391\u2013402.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1594_CR40","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1167\/iovs.08-1712","volume":"49","author":"ML Katz","year":"2008","unstructured":"Katz ML, Coates JR, Cooper JJ, O\u2019Brien DP, Jeong M, Narfstrom K. Retinal pathology in a canine model of late infantile neuronal ceroid lipofuscinosis. Investig Ophthalmol Vis Sci. 2008;49:2686\u201395.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"1594_CR41","doi-asserted-by":"publisher","first-page":"108135","DOI":"10.1016\/j.exer.2020.108135","volume":"198","author":"REH Whiting","year":"2020","unstructured":"Whiting REH, Robinson Kick G, Ota-Kuroki J, Lim S, Castaner LJ, Jensen CA, et al. Intravitreal enzyme replacement inhibits progression of retinal degeneration in canine CLN2 neuronal ceroid lipofuscinosis. Exp Eye Res. 2020;198:108135.","journal-title":"Exp Eye Res"},{"key":"1594_CR42","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1089\/humc.2014.155","volume":"26","author":"SM Petersen-Jones","year":"2015","unstructured":"Petersen-Jones SM, Komaromy AM. Dog models for blinding inherited retinal dystrophies. Hum Gene Ther Clin Dev. 2015;26:15\u201326.","journal-title":"Hum Gene Ther Clin Dev"},{"key":"1594_CR43","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.1016\/j.ymgme.2019.11.157","volume":"129","author":"S Goobie","year":"2020","unstructured":"Goobie S, Bujold J, Dyack S. Intrafamilial variability in late-onset CLN2 disease. Mol Genet Metab. 2020;129:S66\u2013S7.","journal-title":"Mol Genet Metab"},{"key":"1594_CR44","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1111\/epi.13820","volume":"58","author":"N Specchio","year":"2017","unstructured":"Specchio N, Bellusci M, Pietrafusa N, Trivisano M, de Palma L, Vigevano F. Photosensitivity is an early marker of neuronal ceroid lipofuscinosis type 2 disease. Epilepsia. 2017;58:1380\u20138.","journal-title":"Epilepsia"},{"key":"1594_CR45","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.pediatrneurol.2013.08.008","volume":"50","author":"RH Jadav","year":"2014","unstructured":"Jadav RH, Sinha S, Yasha TC, Aravinda H, Gayathri N, Rao S, et al. Clinical, electrophysiological, imaging, and ultrastructural description in 68 patients with neuronal ceroid lipofuscinoses and its subtypes. Pediatr Neurol. 2014;50:85\u201395.","journal-title":"Pediatr Neurol"},{"key":"1594_CR46","first-page":"91","volume":"36","author":"M Horiguchi","year":"1992","unstructured":"Horiguchi M, Miyake Y. Batten disease-deteriorating course of ocular findings. Jpn J Ophthalmol. 1992;36:91\u20136.","journal-title":"Jpn J Ophthalmol"},{"key":"1594_CR47","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1136\/jnnp.40.4.323","volume":"40","author":"G Pampiglione","year":"1977","unstructured":"Pampiglione G, Harden A. So-called neuronal ceroid lipofuscinosis. Neurophysiological studies in 60 children. J Neurol Neurosurg Psychiatry. 1977;40:323\u201330.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1594_CR48","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1177\/0883073816658659","volume":"31","author":"DV Albert","year":"2016","unstructured":"Albert DV, Yin H, De Los Reyes EC, Vidaurre J. Unique characteristics of the photoparoxysmal response in patients with neuronal ceroid lipofuscinosis type 2: can EEG be a biomarker? J Child Neurol. 2016;31:1475\u201382.","journal-title":"J Child Neurol"},{"key":"1594_CR49","doi-asserted-by":"publisher","first-page":"016014","DOI":"10.1117\/1.JBO.19.1.016014","volume":"19","author":"F Folgar","year":"2014","unstructured":"Folgar F, Yuan E, Farsiu S, Toth C. Lateral and axial measurement differences between spectral-domain optical coherence tomography systems. J Biomed Opt. 2014;19:016014.","journal-title":"J Biomed Opt"},{"key":"1594_CR50","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1097\/ALN.0000000000003281","volume":"132","author":"L Vutskits","year":"2020","unstructured":"Vutskits L, Culley DJ. GAS, PANDA, and MASK: reply. Anesthesiology 2020;132:1589\u201390.","journal-title":"Anesthesiology"},{"key":"1594_CR51","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/ALN.0000000000002232","volume":"129","author":"DO Warner","year":"2018","unstructured":"Warner DO, Zaccariello MJ, Katusic SK, Schroeder DR, Hanson AC, Schulte PJ, et al. Neuropsychological and behavioral outcomes after exposure of young children to procedures requiring general anesthesia: the mayo anesthesia safety in kids (MASK) study. Anesthesiology 2018;129:89\u2013105.","journal-title":"Anesthesiology"},{"key":"1594_CR52","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/00003643-200404000-00004","volume":"21","author":"G Iohom","year":"2004","unstructured":"Iohom G, Whyte A, Flynn T, O\u2019Connor G, Shorten G. Postoperative changes in the full-field electroretinogram following sevoflurane anaesthesia. Eur J Anaesthesiol. 2004;21:272\u20138.","journal-title":"Eur J Anaesthesiol"},{"key":"1594_CR53","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s10633-014-9427-0","volume":"128","author":"WB Messenger","year":"2014","unstructured":"Messenger WB, Yang P, Pennesi ME. Ophthalmic findings in an infant with phosphomannomutase deficiency. Doc Ophthalmol. 2014;128:149\u201353.","journal-title":"Doc Ophthalmol"},{"key":"1594_CR54","doi-asserted-by":"publisher","first-page":"190","DOI":"10.3109\/13816810903258829","volume":"30","author":"JP Kelly","year":"2009","unstructured":"Kelly JP, Weiss AH, Rowell G, Seigel GM. Autofluorescence and infrared retinal imaging in patients and obligate carriers with neuronal ceroid lipofuscinosis. Ophthalmic Genet. 2009;30:190\u20138.","journal-title":"Ophthalmic Genet"},{"key":"1594_CR55","doi-asserted-by":"crossref","unstructured":"Wibbeler E, Wang R, Reyes EL, Specchio N, Gissen P, Guelbert N, et al. Cerliponase alfa for the treatment of atypical phenotypes of cln2 disease: a retrospective case series. J Child Neurol. 2020:883073820977997.","DOI":"10.1177\/0883073820977997"},{"key":"1594_CR56","doi-asserted-by":"publisher","first-page":"4537","DOI":"10.1167\/iovs.15-16542","volume":"56","author":"H Lee","year":"2015","unstructured":"Lee H, Purohit R, Patel A, Papageorgiou E, Sheth V, Maconachie G, et al. In vivo foveal development using optical coherence tomography. Investig Ophthalmol Vis Sci. 2015;56:4537\u201345.","journal-title":"Investig Ophthalmol Vis Sci"}],"updated-by":[{"DOI":"10.1038\/s41433-021-01720-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T00:00:00Z","timestamp":1628726400000}}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-021-01594-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-021-01594-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-021-01594-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T12:26:27Z","timestamp":1633004787000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-021-01594-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,16]]},"references-count":56,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["1594"],"URL":"https:\/\/doi.org\/10.1038\/s41433-021-01594-y","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41433-021-01720-w","asserted-by":"object"}]},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,16]]},"assertion":[{"value":"4 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2021","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41433-021-01720-w","URL":"https:\/\/doi.org\/10.1038\/s41433-021-01720-w","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}